Avoro Capital Advisors 13F: Adds $19M to XENE Stake

Avoro Capital Advisors added to its position in Xenon Pharmaceuticals Inc. (NasdaqGM: XENE), raising its stake by 6.5% during the period. The quarterly SEC Form 13F filing shows the health care-focused fund bought an additional 353,333 shares to bring its total holding to 5,777,777 shares. Based on market prices, the investment was valued at roughly $302.9 million at the time of the report. Because 13F filings look backward at holdings from the end of the reporting period, the figures may not reflect the firm's exact position today.

How Avoro Adjusted Its Xenon Holding

Before the transaction, Avoro Capital Advisors held 5,424,444 shares of the neuroscience drug developer. The addition of 353,333 shares represents a 6.5% increase for the fund. This buy stands in contrast to several recent portfolio adjustments by the firm, which completely exited stakes in companies like Ultragenyx Pharmaceutical, PTC Therapeutics, and MoonLake Immunotherapeutics over prior quarters.

Xenon Stock Trades Near Midpoint of 52-Week Range

Shares of Xenon Pharmaceuticals recently changed hands at $52.42, sitting well above the company's 52-week low of $35.97 but below its high of $72.66. The stock trades close to its 200-day moving average of $53.38, while tracking slightly below its 50-day moving average of $61.70. With a beta of 0.62, the stock tends to move less sharply than the broader market.

Analysts Set New Price Targets

Wall Street analysts hold a positive view on the biotechnology company, carrying a consensus recommendation of strong buy across 18 analyst opinions. RBC Capital maintained an outperform rating on September 18, 2026, with a price target of $70.00 down from $81.00. On the same day, Wedbush maintained its outperform rating and adjusted its target from $71.00 to $55.00, while Wells Fargo kept an overweight rating with a target moved from $69.00 to $64.00. Deutsche Bank downgraded the stock to a hold on September 18, 2026, lowering its target to $46.00 from $90.00. Needham maintained a buy rating with a target reduced from $78.00 to $60.00, and Baird maintained an outperform rating with a target lowered from $97.00 to $90.00. Earlier on August 7, 2026, RBC Capital had maintained an outperform rating at an $81.00 target. The overall average analyst price target stands at $74.87.

Focus on Neurological Therapies

Headquartered in Burnaby, Canada, Xenon Pharmaceuticals is a clinical-stage biopharmaceutical company focused on discovering treatments for neurological and psychiatric conditions. Its pipeline includes potassium and sodium channel blockers aimed at epilepsy and major depressive disorder, backed by collaborations with partners like Neurocrine Biosciences. The company employs 358 people and maintains a market capitalization of roughly $3.8 billion.

What to Watch at XENE

Investors tracking Avoro Capital Advisors will learn of any further portfolio changes when the fund files its next round of 13F disclosures with the SEC. Xenon Pharmaceuticals is scheduled to release its next financial results on November 2, 2026. As always, 13F filings provide a historical snapshot of institutional ownership rather than real-time trading data.